Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGB3002 SAD Study in Healthy Participants
NCT07660341Phase 1Recruiting
- Sponsor
- ChainGen Bio
- Start
- Jun 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CGB3002 in Alzheimer's disease (AD) (7 arms), sponsored by ChainGen Bio. Primary endpoint: Adverse Events at 15 weeks. Started Jun 2026; status: recruiting.
02
Drugs
CGB3002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07660341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07660341.